Lena Oberbremer

Learn More
Mammals encode proteins that inhibit viral replication at the cellular level. In turn, certain viruses have evolved genes that can functionally counteract these intrinsic restrictions. Human CD317 (BST-2/HM1.24/tetherin) is a restriction factor that blocks release of human immunodeficiency virus type 1 (HIV-1) from the cell surface and can be overcome by(More)
Human CD317 (BST-2/tetherin) is an intrinsic immunity factor that blocks the release of retroviruses, filoviruses, herpesviruses, and arenaviruses. It is unclear whether CD317 expressed endogenously in rodent cells has the capacity to interfere with the replication of the retroviral rodent pathogen murine leukemia virus (MLV) or, in the context of(More)
Clinical trials of the first approved integrase inhibitor (INI), raltegravir, have demonstrated a drop in the human immunodeficiency virus type 1 (HIV-1) RNA loads of infected patients that was unexpectedly more rapid than that with a potent reverse transcriptase inhibitor, and apparently dose independent. These clinical outcomes are not understood. In(More)
Open Access Oral presentation HIV-1 antagonism of CD317/tetherin is species-specific and involves Vpu-mediated proteasomal degradation of the intrinsic immunity factor Christine Goffinet1, Ina Allespach1, Stefanie Homann1, Hanna-Mari Tervo1, Anja Habermann1, Daniel Rupp1, Lena Oberbremer1, Christian Kern1, Nadine Tibroni1, Sonja Welsch1,2,3, Jacomine(More)
  • 1